exRNAdisease

Entry Detail

---



General Information

Database ID: exR0089020 RNA Name: hsa-miR-519b-3p RNA Type: miRNA Chromosome: chr19 Starnd: + Coordinate: Start Site(bp): 53695263 End Site(bp): 53695284 External Links: hsa-miR-519b-3p

Disease Information

Disease Name: Breast Cancer Disease Category: Cancers MeSH ID: D001943 Type: Neoplasms/Breast Neoplasms Alias: Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID: GSE101841 Description: Serum microRNA profile of Her2 positive metastatic breast cancer patients Experimental Design: Trastuzumab therapy Case Disease Type: Breast Cancer Case Disease SubType: HER2 positive metastatic breast cancer Case Sample: Breast Cancer Trastuzumab resistant Control Sample: Trastuzumab sensitive Number of Case: 42 Number of Control: 61 Number of Samples: 103

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand EEA1 chr12 92770637 92929331 - MBP chr18 76978827 77133683 - RAB31 chr18 9708275 9862551 + APCDD1 chr18 10454635 10489949 + FAM102A chr9 127940582 127980989 - CCSAP chr1 229321011 229343294 - FAM13A chr4 88725955 89111398 - RUNDC1 chr17 42980565 42993690 + TMEM50A chr1 25338317 25362361 + ARL4A chr7 12686856 12690958 + EIF5A2 chr3 170888418 170908644 - SYAP1 chrX 16719612 16765340 + LONP2 chr16 48244300 48363122 + PXDN chr2 1631887 1744852 - IFNAR1 chr21 33324429 33359864 + MAPK6 chr15 51952106 52067375 + PLAGL2 chr20 32192504 32207743 - SCAMP2 chr15 74843730 74873365 - SEC16A chr9 136440096 136483759 - KLHL28 chr14 44924319 45042322 - ADAR chr1 154582057 154628013 - CHD9 chr16 53055033 53329150 + CLCN6 chr1 11806096 11848079 + CLIP4 chr2 29097705 29189643 + WDR82 chr3 52254434 52288020 - SMAD7 chr18 48919853 48952052 - RGMA chr15 93035273 93089204 - SASH1 chr6 148272304 148552048 + OCRL chrX 129539849 129592561 + TAOK3 chr12 118149801 118372907 - miRNA targets: NA circRNA targets: circRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand hsa_circ_0001495 chr5 68470703 68471364 + hsa_circ_0000494 chr13 76134888 76143643 + hsa_circ_0000018 chr1 15860731 15863309 + lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AC002094.1 chr17 28357647 28381697 + AC010542.4 chr16 66549280 66551189 + AC015871.3 chr15 79920195 79922455 - AC021078.1 chr5 149494314 149504670 - AC021092.1 chr19 44103007 44113183 - AC024940.6 chr12 31280422 31280895 - AC087477.2 chr15 96354237 96405235 + AC243964.3 chr19 44631573 44725217 - AL137782.1 chr13 75549773 75807120 + AL158206.1 chr9 19453209 19455173 + CKMT2-AS1 chr5 81201341 81301565 - EPB41L4A-AS1 chr5 112160526 112164818 + ERICD chr8 140636281 140638283 + H19 chr11 1995176 2001470 - HAGLR chr2 176164051 176188958 - HOTAIR chr12 53962308 53974956 - MAGI2-AS3 chr7 79452877 79471208 + MIR17HG chr13 91347820 91354579 + NEAT1 chr11 65422774 65445540 + STAG3L5P-PVRIG2P-PILRB chr7 100336104 100367831 + XIST chrX 73820649 73852723 - Display:

Experiment Detail

GEO ID: GSE101841 Sample Source: Blood Source Fraction: Serum Platform: GPL23138 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 1808 Sample treatment protocol: NA RNA Extract protocol: Total RNA was extracted from 103 samples with the Plasma RNA Purification Mini Kit (51000, NorgenBiotek Corporation, Canada), following manufacturer's instructions. RNA library preparation protocol: Total RNA extracted from 600ul serum was employed with 100 nmol/L of pCp-DY647 and 15 Units of T4 RNA ligase in a total reaction volume of 20 ul at 16°C overnight.

Reference

PMID: 29691399 Title: A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients. Author: Li H, Liu J, Chen J, Wang H, Yang L, Chen F, Fan S, Wang J, Shao B, Yin D, Zeng M, Li M, Li J, Su F, Liu Q, Yao H, Su S, Song E Journal: Nat Commun. 2018 Apr 24;9(1):1614. Description: MicroRNAs (miRNAs) have been used to predict therapeutic effects for various cancers, but whether miRNAs can serve as biomarkers for HER2+ metastatic breast cancer (MBC) patients remains unclear.